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Abstract: T-cell malignancies have distinct biochemical, immunologic, and clinical features 
which set them apart from non-T-cell malignancies. In the past, T-cell leukemia portended a 
worse prognosis than leukemia of B-cell origin. Cure rates have improved with intensiﬁ  cation 
of therapy and advanced understanding of the molecular genetics of T-cell malignancies. Further 
advances in the treatment of T-cell leukemia will require the development of novel agents that 
can target speciﬁ  c malignancies without a signiﬁ  cant increase in toxicity. Nelarabine (2-amino-
9β-D-arabinosyl-6-methoxy-9H-guanine), a synthesized guanosine nucleoside prodrug of ara-G 
(9-β-D-arabinofuranosylguanine), recently received accelerated approval by the U.S. Food and 
Drug Administration (FDA) for the treatment of relapsed/refractory T-ALL and T-LBL in adults 
and children. Nelarabine is water soluble and rapidly converted to ara-G, which is speciﬁ  cally 
cytotoxic to T-lymphocytes and T-lymphoblastoid cells. Clinical and pharmacokinetic investi-
gations have established that nelarabine is active as a single agent which has led to exploration 
of an expanded role in the treatment of T-cell hematologic malignances.
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Background
The cure rate for acute lymphoblastic leukemia (ALL) has steadily increased since the 
1960’s, with the ﬁ  rst success coming in the pediatric population (Smith et al 1996; Gaynon 
et al 2000; Conter et al 2000; Pui et al 2004). With contemporary therapy, the 5-year 
event-free survival rate (EFS) is approximately 80% for children and 40% for adults (Pui 
et al 1998, 2003). Advances in supportive care, precise risk assessment, intensiﬁ  cation 
of therapy, and advances in understanding the molecular genetics of leukemia cells have 
led to an improved outcome. T-cell lymphoid malignancies have distinct biochemical, 
immunologic, and clinical features which set them apart from non-T-cell malignancies 
(Crist et al 1988; Garrand et al 1990; Bash et al 1993; Uckun et al 1998). For example, 
the observation that T-cell lineage blasts form fewer methotrexate polyglutamates than 
that of B-cell blasts has led to the intensiﬁ  cation of methotrexate for optimal response 
(Pui et al 2002). Advances such as these, along with the introduction of high-dose, multi-
agent pulse chemotherapy, have signiﬁ  cantly improved the EFS of children with T-cell 
ALL (T-ALL) from 15%–20% three decades ago to approximately 75% on the most 
recent published regimens (Reiter et al 1994; Schorin et al 1994). Despite intensiﬁ  cation 
of therapy, the EFS rates seem to have plateaued, suggesting that further intensiﬁ  cation 
of existing treatments is unlikely to substantially improve outcome. In addition, high 
dose chemotherapy leaves patients with an increased risk of treatment-related toxicity, 
long term sequelae, and secondary malignancies. Therefore, the development of novel 
agents with improved efﬁ  cacy and safety proﬁ  les will be important to advance survival 
in patients with T-cell malignancies. With the proven efﬁ  cacy of antimetabolites such Therapeutics and Clinical Risk Management 2007:3(6) 1136
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as methotrexate and cytarabine in treatment regimens for 
T-ALL and T-cell lymphoblastic lymphoma (T-LBL), the 
development of purine nucleoside analogs with preferential 
cytotoxicity toward T-lymphocytes may be a promising 
strategy. Nelarabine (2-amino-9β-D-arabinosyl-6-methoxy-
9H-guanine, compound GW506U78), a prodrug of ara-G 
(9-β-D-arabinofuranosylguanine), has been recently approved 
by the US Food and Drug Administration (FDA) for the treat-
ment of relapsed/refractory T-ALL and T-LBL in adults and 
children (Cohen et al 2006). This paper will review the devel-
opment of nelarabine, including the chemistry, pharmacology, 
and clinical data of this promising new agent.
Mechanism of action/chemistry
Nucleoside analogs, such as cytarabine, are prodrugs that are 
converted to their active triphosphate form by a series of enzy-
matic phosphorylation steps and then incorporated into DNA 
(Momparler et al 1968; Rodriguez et al 2002). These agents 
have proven highly effective in the treatment of hematologic 
malignancies, including T-ALL and T-LBL. In particular, 
guanine nucleoside analogs generated clinical interest after 
the discovery that a genetic deﬁ  ciency of purine nucleoside 
phosphorylase (PNP) results in a profound T-cell lympho-
penia (Giblett et al 1975). PNP is a ubiquitous enzyme that, 
when deﬁ  cient, leads to a dysfunction of the purine salvage 
pathway and thus elevated plasma deoxyguanosine (dGuo) 
and an intracellular accumulation of its deoxyguanosine 
triphosphate (dGTP) (Giblett et al 1975; Cohen et al 1978). 
Models of PNP deﬁ  ciency further revealed that ara-G was 
speciﬁ  cally toxic to T-lymphocytes and T-lymphoblastoid 
cells, whereas B-lymphocytes did not accumulate high levels 
of dGTP and were less sensitive to deoxyguanosine (Mitchell 
et al 1978; Osborne et al 1983; Fairbanks et al 1990). Despite 
this T-cell speciﬁ  city, the clinical use of the deoxyguanosine 
analog ara-G was limited because of the poor solubility of the 
compound (Cohen 1983). However, investigators developed 
the 6-methoxy prodrug of ara-G, nelarabine, that is 10 times 
more water soluble than previous ara-G preparations (Lambe 
et al 1995). Nelarabine is a substrate for adenosine deaminase 
which converts the prodrug to ara-G (Figure 1). Ara-G is 
transported into T-lymphoblastoid cells by two facilitative 
nucleoside transport systems that differ in their sensitivity to 
inhibition by nitrobezylthioinosine (Prus et al 1990). However, 
this inhibition is not the rate-limiting step of its cellular metabo-
lism. Rather, it is the initial conversion to its monophosphate 
form (ara-GMP) by both deoxycytidine kinase (dCyd) and 
dGuo kinase (Rodriguez et al 2002). Ara-GTP subsequently 
competes with dGTP in leukemia blasts for incorporation into 
DNA (Gandhi et al 1995). The incorporation of ara-GTP into 
DNA inhibits DNA synthesis, resulting in chain termination 
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Figure 1 Conversion of nelarabine to ara-G by adenosine deaminase.Therapeutics and Clinical Risk Management 2007:3(6) 1137
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and apoptosis (Rodriguez et al 1999). In addition, T-cell 
selective cytoxicity investigations reveal that in addition to a 
higher accumulation of ara-GTP in T-cells, the induction of 
the Fas-mediated cell death pathway further enhances T-cell 
kill. (Rodriguez et al 2003). With the development of this 
ara-G prodrug, investigation into the T-cell cytotoxicity of this 
agent moved forward. Details of recent clinical investigations 
of nelarabine are shown in Table 1.
Clinical evaluation
Based on the favorable chemical and mechanistic properties 
of nelarabine, the initial Phase I clinical trial was conducted 
on 93 adults and children with refractory hematologic 
malignancies (Kurtzberg et al 2005). Nelarabine was admin-
istered daily as a 1-hour infusion for 5 days. Dose levels 
ranged from 5 mg/kg to 75 mg/kg. The maximum tolerated 
dose (MTD) was determined to be 40 mg/kg and 60 mg/kg 
daily for 5 days in adult and pediatric patients, respectively. 
Of the 93 patients enrolled, 39 were diagnosed with malig-
nancies of the T lymphoid lineages (T-ALL and T-LBL). 
Twenty-three percent (9) of patients with T-ALL/T-LBL 
achieved a complete response (CR), and 31% (12) achieved 
a partial response (PR). Of these responders, 71% had at 
least 2 prior relapses and 48% had failed stem cell transplant 
(SCT). Consistent with preclinical investigations, the dose 
limiting toxicity (DLT) of nelarabine was neurotoxicity. Half 
the children and 85% of adults enrolled on the initial Phase I 
study experienced reversible neurotoxicity including weak-
ness, ataxia, and confusion. Transient somnolence, malaise 
and fatigue beginning at 6–8 days after therapy were reported 
most frequently, mainly in adults. Coma was observed in 
3 of 4 adults and 1 child at the 60 mg/kg dose level (approxi-
mately 1.8 g/m2) and 2 of 31 adults treated at the 40 mg/kg
dose level. No neurotoxicity was observed in children at the 
40 mg/kg dose level (approximately 1.2 g/m2). Both ataxia 
(2 children, 5 adults) and gait disorder (0 children, 12 adults) are 
neurologic events that may be reﬂ  ective of cerebellar toxicity. 
Other cerebellar events, such as tremors or dysmetria, are not 
mentioned by the authors. These neurologic events are of 
particular interest as other purine nucleoside analogs such as 
ﬂ  udarabine, especially when combined with cytarabine, have 
been associated with speciﬁ  c cerebellar toxicity (Vidarsson 
et al 2001). A more thorough review of the neurotoxcicity 
of compound 506U in both adults and children as presented 
to the FDA can be found in Tables 2 and 3.
After the Phase I trial demonstrated the potential of 
nelarabine in T-cell malignancies, a pediatric Phase II trial 
of nelarabine was conducted by the Children’s Oncology 
Group (COG) (Berg et al 2005). The trial accrued 153 patients 
less than 21 years of age with recurrent or refractory T-ALL 
and T-LBL. Patients were stratiﬁ  ed depending on the site 
of relapse and number of prior relapses. The strata were as 
follows: stratum 1:25% bone marrow blasts in ﬁ  rst relapse; 
stratum 2:25% blasts in  second relapse; stratum 3: 
positive CSF; stratum 4: extramedullary (non-CNS) relapse. 
Nelarabine was initially administered at a dose of 1.2 g/m2 IV 
over I hour daily for 5 days. Because of grade 4 neurotoxic-
ity at this dose level, the dose was de-escalated twice to a 
ﬁ  nal dose of 650 mg/m2/day for 5 days. In addition, because 
it seemed likely that the nelarabine dose would be lower in 
future studies in combination with other cytotoxic agents, the 
doses for patients in stratum 3 and stratum 4 were reduced 
to 400 mg/m2. Patients in stratum 1 had an overall response 
rate of 55%, with 16 CRs and 2 PRs. Patients in stratum 2 
had an overall response rate of 27%, with 7 CRs and 1 PR. 
Of 21 assessable patients in stratum 3, the overall response 
Table 1 Clinical trials of nelarabine
Population (Phase)  # of patients  Disease type  Nelarabine  Schedule  CR(%)  PR(%)  Reference
     (g/m2)      
Adult and pediatric (I)   93   Leukemia +   escalating  Daily for 5 days  11  20  Kurtzbuerg et al 2005
   Lymphoma
Adult (II)   38   T-cell   1.5   Days 1, 3, 5   26   5   DeAngelo et al 2002 
Adult (II)   53   T-cell   1.5   Days 1, 3, 5   47   13   Geokbuget et al 2005 
Adult (II)   23   Non-Hodgkin’s  1.5  Days 1, 3, 5   11  36  Goy et al 2003
   lymphoma
Adult (I)   13   Indolent leukemia/  1.2  Days 1, 3, 5  15  31  Gandhi et al 2001
nelarabine/ﬂ  udarabine    T-cell ALL             
Pediatric (II)   136   T-cell   1.2, 0.6, 0.4   Daily for 5 days   35   10   Berg et al 2005 
Pediatric (pilot)   87   T-cell   0.4, 0.6   Daily for 5 days   not published     Dunsmore et al 2006
nelarabine/augmented BFM  
Abbreviations: CR, complete remission; PR, CR without platelet recovery and partial remission; T-cell, T-cell acute lymphoblastic leukemia and T-cell lymphoblastic 
lymphoma.Therapeutics and Clinical Risk Management 2007:3(6) 1138
Cooper
rate was 33% with 5 CRs and 2 PRs. Patients in stratum 4 
had an overall response rate of 14%, with no CR’s. Eighteen 
patients in this study experienced  Grade 3 neurologic side 
effects, the most common being reversible somnolence and 
peripheral neuropathy manifested by weakness, numbness, 
and/or paresthesias, predominantly in the lower extremities. 
Other than lower extremity weakness, there is no speciﬁ  c 
report of cerebellar toxicity in this study. The authors of this 
study reason that this difference in response rate between 
patients in ﬁ  rst relapse versus subsequent relapse may be 
due to the amount of previous therapy and resultant resistant 
disease, and therefore nelarabine may be even more effective 
in newly diagnosed patients.
A Phase II trial was conducted by The Cancer and 
Leukemia Group (CALGB) and Southwestern Oncology 
Group (SWOG) on 40 patients ages 16 to 60 years with 
relapsed or refractory T-ALL (22 patients) and T-LBL 
(18 patients) (De Angelo et al 2002). All patients were 
refractory to at least one prior regimen or had relapsed prior 
to therapy with nelarabine. An alternate day schedule of 
single-agent nelarabine was implemented and 1.5 gm/m2 was 
administered on days 1, 3, and 5 of a 21-day cycle. The ratio-
nale for this schedule was two-fold. First, it was designed 
to reduce the neurotoxicity which was more pronounced in 
adult patients on the initial Phase I study (Kurtzberg et al 
2005). Second, the pharmacologic rationale was based on the 
prolonged retention of ara-GTP in leukemia cells (Rodriguez 
et al 1997; Gandhi et al 2001). Of the 38 patients evaluable 
for response, 6 patients with T-ALL achieved a CR (29%) 
and 2 patients achieved a PR (9%). For those with T-LBL, 
4 patients achieved a CR (24%). The overall response rate 
for all evaluable patients on this study was 32%. Although 
most reported toxicities were similar to the 5-day schedule 
in the initial pediatric phase I and II studies, neurotoxicity 
was negligible on this 3-day schedule.
The German Multicenter ALL study group (GMALL) 
reported favorable results in a Phase II study of 53 patients 
studied with relapsed/refractory T-ALL and T-LBL
 (Geokbuget et al 2005). The median age of patients enrolled 
was 31 years. Thirty-six patients were in ﬁ  rst relapse (68%), 
7 were in second relapse (13%), 7 patients had relapsed after 
SCT (13%), and 3 patients were refractory to their initial 
induction regimen (6%). Similar to the CALGB study, 
nelarabine was administered on days 1, 3, and 5 at a dose 
of 1.5 g/m2. Overall, 25 patients achieved a CR (47%), and 
7 patients achieved a PR (13%), for an overall response 
rate of 60%. Patients with T-ALL had the most favorable 
response with 76% achieving a CR. Importantly, 75% of 
patients achieving a CR went on to receive a stem cell 
transplant (SCT).
Investigators at MD Anderson Cancer Center com-
pleted a Phase II study which evaluated therapy in patients 
with non-Hodgkin’s lymphoma (Goy et al 2003). Thirteen 
patients with peripheral T-cell lymphoma (PTCL) and 
10 patients with low-grade B-cell lymphoma were eligible. 
The age range for patients on this trial was 33–81 years. All 
patients had failed 1–3 previous chemotherapy regimens. 
An alternating day schedule of nelarabine at 1.5 g/m2 was
administered on days 1, 3, and 5. In this study, the course of 
therapy was repeated every 28 days, whereas the previous 
adult studies repeated every 21 days. Of the 17 evaluable 
patients, 2 patients achieved a CR (11%), and 6 achieved 
Table 2 Nelarabine neurological toxicity in adult patients 
(n = 103) as presented to the FDA Oncology Drugs Advisory 
Committee
Adverse event   All grades (%)   Grades 3/4 (%) 
Somnolence   23   0 
Hypoesthesia   17   2 
Paresthesia   15   2 
Peripheral neuropathy (sensory)  13   0 
Peripheral neuropathy (motor)  7   1 
Peripheral neuropathy (unspeciﬁ  ed)  5   1 
Ataxia   9   2 
Depressed level of consciousness  6   1 
Tremor   5   0 
Neuropathy   4   0 
Amnesia   3   0 
Dysgeusia   3   0 
Balance disorder   2   0 
Sensory loss   2   0 
Derived from Cohen et al (2006).
Table 3 Nelarabine neurological toxicity data in pediatric 
patients (n = 84) as presented to the FDA Oncology Drugs 
Advisory Committee
Adverse event   All grades (%)  Grades 3/4 (%)
Headache   17   6 
Somnolence   7   2 
Hypoesthesia   6   4 
Peripheral neuropathy (sensory)  6   6 
Peripheral neuropathy (motor)  4   2 
Peripheral neuropathy (unspeciﬁ  ed)  6   2 
Convulsion   4   4 
Motor dysfunction   4   1 
Nervous system disorder   4   0 
Paresthesia   4   1 
Tremor   4   0 
Ataxia   2   1 
Derived from Cohen et al (2006).Therapeutics and Clinical Risk Management 2007:3(6) 1139
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a PR (36%). Included in these responses were 4 patients 
with PTCL (2CR and 2PR for a response rate of 50%) and 
4 patients with low-grade B-cell lymphoma (4PR for a 
response rate of 44%).
The ﬁ  rst study combining nelarabine with another cyto-
toxic agent was performed by investigators at MD Anderson 
Cancer Center (Gandhi et al 2001). Thirteen patients were 
enrolled on the pilot protocol, most of whom had indolent 
leukemia, to receive a combination of fludarabine and 
nelarabine. Nelarabine, dosed at 1.5 g/m2 was administered 
on days 1, 3, and 5, in combination with 30 mg/m2 of ﬂ  uda-
rabine on days 3 and 5. Patient diagnoses included 9 with 
indolent leukemia, 2 had T-ALL, 1 CML, and 1 with mycosis 
fungoides. The ﬂ  udarabine was administered 4 hours prior 
to nelarabine to enhance biochemical modulation. It was 
postulated that ﬂ  udarabine, by inhibiting ribonucleotide 
reductase, would increase ara-GTP accumulation in leuke-
mic cells. This hypothesis was supported by investigations 
reporting that higher intracellular concentrations of ara-GTP 
were achieved when human leukemia cells were incubated 
with both ara-G and ﬂ  udarabine compared with ara-G alone 
(Rodriguez et al 1997). The overall response rate for patients 
entered in this trial was 46%, with 15% achieving a CR and 
31% achieving a PR. Two patients with T-ALL and 1 patient 
with T-prolymphocytic leukemia (T-PLL) achieved a CR.
Three patients with B-lineage chronic lymphocytic leukemia 
(B-CLL) achieved a PR. Of particular interest, 4 patients with 
either T-PLL or B-CLL were refractory to previous treat-
ment with ﬂ  udarabine (2 B-CLL and 1 T-PLL) or cladribine 
(1 T-PLL) alone. The authors suggest these responses are due 
to the superior pharmacokinetics of nelarabine and that these 
nucleoside analogs may not be cross-resistant.
To assess the feasibility and safety of adding nelarabine 
to an intensive Berlin-Frankfurt-Munster (BFM) regimen 
in children with newly diagnosed T-ALL, COG initiated a 
2-stage pilot study (Reiter et al 1994; Dunsmore et al 2006). 
The end-point of this randomized pilot was toxicity. Eighty-
seven evaluable patients were accrued. In stage I, only slow 
early responders, deﬁ  ned as 1000 peripheral blood blasts 
on day 8 of prednisone treatment or 1% minimal residual 
disease (MRD) at day 36 of induction therapy, were included. 
They were randomized either to receive (11 evaluable 
patients) or not to receive (16 evaluable patients) nelara-
bine 400 mg/m2/day for 5 days. No signiﬁ  cant differences 
in toxicity between the two groups were noted. Stage II of 
the trial was limited to 61 evaluable patients with high risk 
T-ALL by National Cancer Institute (NCI) criteria. Patients 
were randomized to receive five courses of nelarabine 
at the Phase II MTD of 650 mg/m2/day (10 patients) or 
400 mg/m2/day (51 patients) in combination with BFM che-
motherapy. Toxicities were compared between the regimens 
with nelarabine (71 evaluable patients) and without nelara-
bine (16 evaluable patients). There were no differences in 
the incidence of peripheral neuropathy (5/71 with nelarabine 
vs 1/16 without nelarabine p = 1.0) or central neurotoxicity 
(2/71 with nelarabine vs 2/16 without nelarabine). The only 
difference in toxicities between regimens was a decrease in 
neutropenia and infection in the nelarabine arms (27/71 with 
nelarabine vs 13/16 without nelarabine p = 0.0021). There 
were no differences in toxicities between the two dose levels 
(650 mg/m2/day vs 400 mg/m2/day). Efﬁ  cacy data from this 
study have not been published. The authors concluded that 
the addition of nelarabine to intensive chemotherapy for 
children with T-ALL was feasible with acceptable toxicity.
Pharmacology
The initial Phase I study of nelarabine published by Kurtz-
berg et al included pharmacokinetic and pharmacodynamic 
analysis on 78 of the 93 patients enrolled on the trial (Gandhi 
et al 1998; Kisor et al 2000). When administered by IV infu-
sion over 1 hour, the maximum plasma concentration (Cmax) 
is reached near the end of infusion and is directly propor-
tional to the dose administered in the range of 5–75 mg/kg. 
Although there was wide patient variability, the volume of 
distribution and systemic clearance of nelarabine did not 
signiﬁ  cantly differ between children and adults. Ninety-four 
percent of the administered dose of nelarabine is converted to 
ara-G in approximately 1 hour. The elimination half-life of 
nelarabine is less than 20 minutes and is similar in children 
and in adults. This short half-life is predominately explained 
by the mole to mole conversion of nelarabine to ara-G via 
adenosine deaminase (Kisor et al 2000).
After the rapid formation of ara-G from nelarabine, ara-G 
is then eliminated via phosphorylytic cleavage of the glyco-
sidic bond by PNP to form guanine. Guanine is then deami-
nated to form xanthine, which is subsequently oxidized to 
uric acid. The elimination half life of ara-G is approximately 
3 hours in adults and 2.1 hours in children. This difference in 
half-life can be attributed to a 30% higher clearance of ara-G 
in children compared with adults (Kisor et al 2000).
The intracellular pharmacokinetics of ara-GTP were 
investigated in patients enrolled in the initial Phase I clinical 
trial (Gandhi et al 1998). Although there was intrapatient 
variability, there was a dose dependent, linear increase in the 
accumulation of intracellular ara-GTP. Ara-GTP in malig-
nant B and T lymphocytes is retained for a median duration Therapeutics and Clinical Risk Management 2007:3(6) 1140
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of greater than 24 hours. In general, however, retention of 
ara-GTP was longer in T lymphoblastoid cells than in other 
leukemic blasts. Furthermore, malignant cells from patients 
who achieved a CR or PR had higher accumulation of ara-
GTP than those who failed to respond (ara-GTP 150 µmol/L 
in responders and 44 µmol/L in non-responders).
The modulatory effect of ﬂ  udarabine on intracellular 
ara-GTP concentration has also been evaluated (Gandhi et al 
2001). Nelarabine (1.2 g/m2) was given on days 1, 3, and 5, 
and was preceded 4 hours earlier on days 3 and 5 by intra-
venous administration of 30 mg/m2 of ﬂ  udarabine. Plasma 
pharmacokinetics revealed that ﬂ  udarabine infusion on days 
3 and 5 did not signiﬁ  cantly effect the linear accumulation 
and elimination of nelarabine or ara-G. The elimination 
half-life of nelarabine in this combination trial did not differ 
signiﬁ  cantly from that found in the single-agent Phase I trial. 
Although it was postulated that administration of ﬂ  udarabine 
prior to nelarabine would increase the intracellular concen-
tration of ara-GTP, intracellular pharmacokinetic evaluation 
revealed there was no difference in the overall AUC (0→∞) 
before and after ﬂ  udarabine administration. The median 
peak intracellular ara-GTP concentrations were signiﬁ  cantly 
different between the responders versus the non-responders 
(890 µmol/L vs 30 µmol/L). These data suggest that the 
accumulation of ara-GTP may not only predict the efﬁ  cacy 
of nelarabine given alone, but also in combination with other 
chemotherapeutic agents.
Conclusion
The rates of response and overall survival of patients with 
T-ALL and T-LBL have improved with intensiﬁ  cation of 
therapy and with our understanding of the molecular basis 
of the disease. In addition, advances in risk stratiﬁ  cation 
have led to intensiﬁ  cation of therapy for patients at higher 
risk of relapse. Despite these advances, the outcomes for 
patients who relapse is dismal, as salvage rates are modestly 
effective and remissions are not durable (Chessels 2003). 
Therefore, the development of new agents that have T-cell 
speciﬁ  city is an important strategy in improving the survival 
of these patients. Nelarabine serves as an effective prodrug 
to generate ara-G in the plasma and intracellular GTP in 
leukemic blasts and is speciﬁ  cally toxic to T-lymphocytes 
and T-lymphoblasts. Further, accumulation of intracellular 
GTP correlates with response. (Gandhi et al 1998; Kisor et al 
2000) Clinical and pharmacokinetic studies have established 
that nelarabine is active as a single agent in the treatment of 
T-cell malignancies (Berg et al 2005). Based on the favor-
able pharmacokinetic proﬁ  le and encouraging clinical data, 
nelarabine received accelerated approved for the treatment 
of relapsed or refractory T-ALL and T-LBL.
To convert to full approval, investigators need to demon-
strate subsequent conﬁ  rmation of clinical beneﬁ  t. To this end, 
the COG plans to initiate a Phase III trial testing the efﬁ  cacy 
of nelarabine 650 mg/m2/day in combination with augmented 
BFM chemotherapy in patients with intermediate risk T-cell 
ALL. This protocol is based on pilot data demonstrating that 
this combination is feasible with acceptable toxicity (Dunsmore 
et al 2006). To re-address concerns about neurotoxicity, there 
will be an initial safety phase of therapy open only to those at 
high risk for relapse (eg, M2 marrow and/or minimal residual 
disease 1% at end of induction). If the therapy is tolerated, 
all patients with intermediate and high risk for relapse will be 
included, thereby increasing the amount of patients that may 
beneﬁ  t from this T-cell speciﬁ  c agent. As there is evidence that 
T-lymphoblasts are more sensitive to higher doses of metho-
trexate, a randomization between standard and high doses of 
methotrexate will be evaluated for low, intermediate, and high 
risk patients with T-ALL (William Carroll, pers comm).
To maximize its potential, the development of nelarabine 
should include rationally designed combinations based on its 
mechanism of action, selective cytotoxicity, and metabolic 
activation. Future trials may study an expanded role of 
nelarabine in stem cell transplant by evaluating it as a T-cell 
speciﬁ  c bone marrow purging agent (Gravatt et al 1993). 
Also, the dosing schedule differs for children and adults. 
Currently, pediatric patients receive 5 consecutive days of 
nelarabine while adults receive doses on days 1, 3, and 5. The 
alternate day dosing is based on the long retention time of 
ara-GTP in T-lymphoblasts and is supported by the decreased 
incidence of neurotoxicity in adult clinical trials (Gandhi 
et al 1998; DeAngelo et al 2002). Future clinical studies in 
pediatric patients may choose to explore alternative doses 
and schedules of nelarabine administration.
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